{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:14:45Z","timestamp":1778768085950,"version":"3.51.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cjco.2026.01.011","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:56:38Z","timestamp":1770047798000},"page":"569-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are Angiotensin-Converting Enzyme Inhibitors Effective in the Treatment of Hypertension in Black Patients?"],"prefix":"10.1016","volume":"8","author":[{"given":"Victoria","family":"Nkunu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross T.","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminu K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-2784","authenticated-orcid":false,"given":"Jennifer","family":"Ringrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.01.011_bib1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.01.011_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.01.011_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cjco.2026.01.011_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM198812083192305","article-title":"Converting-enzyme inhibitors in the treatment of hypertension","volume":"319","author":"Williams","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib6","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.01.011_bib7","first-page":"596","article-title":"Hypertension Canada\u2019s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.01.011_bib8","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0889-8529(05)70237-1","article-title":"Pathophysiology and treatment implications of hypertension in the African-American population","volume":"26","author":"Rahman","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"Suppl 1","key":"10.1016\/j.cjco.2026.01.011_bib11","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1097\/00000441-199512000-00016","article-title":"Racial differences in the pathogenesis of hypertension","volume":"310","author":"Calhoun","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cjco.2026.01.011_bib12","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1161\/01.CIR.0000129087.81352.7A","article-title":"Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases","volume":"109","author":"Kalinowski","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.01.011_bib13","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.01.011_bib14","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cjco.2026.01.011_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1185\/0300799009117011","article-title":"Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage","volume":"16","author":"Flack","year":"2000","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjco.2026.01.011_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2023.11.921","article-title":"Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus","volume":"153","author":"Mathey","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cjco.2026.01.011_bib18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2105\/AJPH.90.11.1699","article-title":"Why genes don\u2019t count (for racial differences in health)","volume":"90","author":"Goodman","year":"2000","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cjco.2026.01.011_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ajpa.24200","article-title":"Skin color and race","volume":"175","author":"Jablonski","year":"2021","journal-title":"Am J Phys Anthropol"},{"key":"10.1016\/j.cjco.2026.01.011_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1037\/0003-066X.60.1.16","article-title":"Race as biology is fiction, racism as a social problem is real: anthropological and historical perspectives on the social construction of race","volume":"60","author":"Smedley","year":"2005","journal-title":"Am Psychol"},{"key":"10.1016\/j.cjco.2026.01.011_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJMms2004740","article-title":"Hidden in plain sight\u2014reconsidering the use of race correction in clinical algorithms","volume":"383","author":"Vyas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.4463","article-title":"The pillars of health disparities science-race, ethnicity, and socioeconomic status","volume":"4","author":"P\u00e9rez-Stable","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.cjco.2026.01.011_bib23","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.numecd.2022.08.002","article-title":"Differences in the risk of cardiovascular disease across ethnic groups: UK Biobank observational study","volume":"32","author":"Razieh","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cjco.2026.01.011_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.122.060199","article-title":"Disparities in cardiovascular mortality between Black and White adults in the United States, 1999 to 2019","volume":"146","author":"Kyalwazi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.01.011_bib25","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.cjco.2021.09.014","article-title":"Racism and cardiology: a global call to action","volume":"3","author":"Banerjee","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.01.011_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025271","article-title":"Locking the revolving door: racial disparities in cardiovascular disease","volume":"12","author":"Velarde","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.01.011_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jch.13824","article-title":"Association of West African ancestry and blood pressure control among African Americans taking antihypertensive medication in the Jackson Heart Study","volume":"22","author":"Van Tassell","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2026.01.011_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1089\/heq.2023.0064","article-title":"The self-fulfilling process of clinical race correction: the case of eighth joint national committee recommendations","volume":"7","author":"Savage","year":"2023","journal-title":"Health Equity"},{"key":"10.1016\/j.cjco.2026.01.011_bib29","article-title":"First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care","volume":"371","author":"Sinnott","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2026.01.011_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3122\/jabfm.2022.01.210276","article-title":"Differences in hypertension medication prescribing for Black Americans and their association with hypertension outcomes","volume":"35","author":"Holt","year":"2022","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.HYP.0000127924.67353.86","article-title":"Determinants of blood pressure response to quinapril in Black and White hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial","volume":"43","author":"Mokwe","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/01.HYP.0000118019.28487.9c","article-title":"Overlap between Whites and Blacks in response to antihypertensive drugs","volume":"43","author":"Sehgal","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0895-7061(01)02195-1","volume":"14","author":"Laragh","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ajh\/hpae093","article-title":"Evolving the role of Black race in hypertension therapeutics","volume":"37","author":"Flack","year":"2024","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-90-1-19","article-title":"Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients","volume":"90","author":"Brunner","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib36","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study [letter]","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.01.011_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.608037","article-title":"Corrigendum: racial and sex differences in the response to first-line antihypertensive therapy","volume":"7","author":"Clemmer","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib40","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjco.2026.01.011_bib42","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinte.1990.00040031707020","article-title":"A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive Blacks","volume":"150","author":"Saunders","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12916-020-01530-z","article-title":"Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis","volume":"18","author":"Seeley","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11739-016-1422-x","article-title":"Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity","volume":"11","author":"Brewster","year":"2016","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib45","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib46","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1099-1557(199605)5:3<149::AID-PDS222>3.0.CO;2-I","article-title":"Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in Blacks than Whites","volume":"5","author":"Burkhart","year":"1996","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjco.2026.01.011_bib48","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.01.011_bib49","first-page":"1947","article-title":"I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents","volume":"144","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Wright","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00004872-198907000-00001","article-title":"Varying responses to hypotensive agents in different racial groups: Black versus White differences","volume":"7","author":"Seedat","year":"1989","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.1982.165","article-title":"Responses to captopril and hydrochlorothiazide in Black patients with hypertension","volume":"32","author":"Moser","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjco.2026.01.011_bib53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/clpt.1983.101","article-title":"Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril","volume":"33","author":"Chrysant","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjco.2026.01.011_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/jch.13751","article-title":"2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network","volume":"22","author":"Kario","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2026.01.011_bib55","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjco.2026.01.011_bib56","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41371-024-00960-z","article-title":"Position statement on hypertension by Indian Society of Hypertension, 2023","volume":"38","author":"Maheshwari","year":"2024","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib57","first-page":"225","article-title":"2022 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension","volume":"38","author":"Wang","year":"2022","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.cjco.2026.01.011_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40885-019-0124-x","article-title":"2018 Korean Society of Hypertension guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37616\/2212-5043.1328","article-title":"National Heart Center\/Saudi Heart Association 2023 guidelines on the management of hypertension","volume":"35","author":"Alhabeeb","year":"2023","journal-title":"J Saudi Heart Assoc"},{"key":"10.1016\/j.cjco.2026.01.011_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.11622\/smedj.2018007","article-title":"Ministry of Health Clinical Practice Guidelines: Hypertension","volume":"59","author":"Tay","year":"2018","journal-title":"Singapore Med J"},{"key":"10.1016\/j.cjco.2026.01.011_bib61","first-page":"182","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension\u2014a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.cjco.2026.01.011_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15605\/jafes.036.01.01","article-title":"Executive summary of the 2020 clinical practice guidelines for the management of dyslipidemia in the Philippines","volume":"36","author":"Gonzalez-Santos","year":"2021","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"10.1016\/j.cjco.2026.01.011_bib63","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jch.14580","volume":"24","author":"Van Minh","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2026.01.011_bib64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5830\/CVJA-2014-062","article-title":"South African hypertension practice guideline 2014","volume":"25","author":"Seedat","year":"2014","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.cjco.2026.01.011_bib84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1741-7015-11-141","article-title":"Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and \u03b2-adrenergic blockers? A systematic review","volume":"11","author":"Brewster","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib65","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/HJH.0000000000002072","article-title":"Latin American consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome","volume":"37","author":"L\u00f3pez-Jaramillo","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib66","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/jch.14072","article-title":"Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative","volume":"22","author":"DiPette","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cjco.2026.01.011_bib67","first-page":"25","article-title":"7th Brazilian guideline of arterial hypertension: chapter 5\u2014therapeutic decision and targets","volume":"107","author":"Malachias","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cjco.2026.01.011_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib37","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.01.011_bib85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0091-7435(03)00140-3","article-title":"The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives","volume":"37","author":"Erlinger","year":"2003","journal-title":"Prev Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3399\/bjgp20X708053","article-title":"Diagnosis and management of hypertension in adults: NICE guideline update 2019","volume":"70","author":"Jones","year":"2020","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.cjco.2026.01.011_bib70","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2026.01.011_bib86","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.01.011_bib71","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1503\/cmaj.241770","article-title":"Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care","volume":"197","author":"Goupil","year":"2025","journal-title":"CMAJ"},{"key":"10.1016\/j.cjco.2026.01.011_bib87","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000231662.77359.de","article-title":"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"48","author":"Leenen","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib88","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib89","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib90","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.01.011_bib72","first-page":"077","article-title":"Management of hypertension and dyslipidemia in Mexico: evidence, gaps, and approach","volume":"93","author":"Morales-Villegas","year":"2023","journal-title":"Arch Cardiol Mex"},{"key":"10.1016\/j.cjco.2026.01.011_bib73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults\u20142016","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.cjco.2026.01.011_bib74","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2369-14-201","article-title":"Difference in blood pressure response to ACE-inhibitor monotherapy between Black and White adults with arterial hypertension: a meta-analysis of 13 clinical trials","volume":"14","author":"Peck","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cjco.2026.01.011_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejim.2024.04.011","article-title":"Single-pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit?","volume":"126","author":"Coca","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2026.01.011_bib91","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.01.011_bib76","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006986","article-title":"Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial","volume":"6","author":"MacDonald","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.01.011_bib77","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2024.18080","article-title":"Low-dose triple-pill vs standard-care protocols for hypertension treatment in Nigeria: a randomized clinical trial","volume":"332","author":"Ojji","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.01.011_bib78","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","article-title":"Comparison of dual therapies for lowering blood pressure in Black Africans","volume":"380","author":"Ojji","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.01.011_bib79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jacc.2019.04.068","article-title":"From ACE Inhibitors\/ARBs to ARNIs in coronary artery disease and heart failure (part 2\/5)","volume":"74","author":"Leong","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.01.011_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7812\/TPP\/15-052","article-title":"Population care management and team-based approach to reduce racial disparities among African Americans\/Blacks with hypertension","volume":"20","author":"Bartolome","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.cjco.2026.01.011_bib81","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive Black and White patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.01.011_bib82","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/HJH.0000000000001171","article-title":"Hypertension in Blacks: insights from Africa","volume":"35","author":"Rayner","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjco.2026.01.011_bib83","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:36:32Z","timestamp":1778765792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X26000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2589790X26000144"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.01.011","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are Angiotensin-Converting Enzyme Inhibitors Effective in the Treatment of Hypertension in Black Patients?","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}